– QUIGLEY H.A., MAUMENEE A.E.: Long-term follow up of treated open-angle glaucoma. Am. J. Ophthalmol.,1979; 87:519-525. – QUIGLEY H.A., ADDICKS E.M.: Chronic experimental glaucoma in primates: II. Effect of extended intraocular pressure elevation on optic nerve head and axonal transport. Invest. Ophthalmol. Vis. Sci., 1980;19:137-152. – QUIGLEY H.A., BROMAN A-T.: The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol., 2006;90:262267. – PARISI V.: Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5’-diphosphocholine (citicoline): a study of 8 years of follow-up. Doc. Ophthalmol., 2005;110:91-102. – PARK C.H., KIM Y.S., NOH H.S., CHEON E.W., YANG Y.A., YOO J.M., CHOI W.S., CHO G.J.: Neuroprotective effect of citicoline against KA-induced neurotoxicity in the rat retina. Exp. Eye Res., 2005;81:350-358. – PECORI-GIRALDI J., VIRNO M., COVELLI G.P., GRECCHI G., DE GREGORIO F.: Therapeutic value of citicoline in the treatment of glaucoma. Int. Ophthalmol., 1989; 13: 109-115. – PESCOSOLIDO N., IMPERATRICE B.: Glaucoma primario ad angolo aperto – Aspetti eziopatogenetici. Canelli (AT), Fabiano Editore, 2006. – RAO A.M., HATCHER J.F., DEMPSEY R.J.: Does CDP-choline modulate phospholipase activities after transient forebrain ischemia? Brain Res., 2001;893:268-272. – RICARD C.S., PENA J.D., HERNANDEZ M.R.: Differential expression of neuronal cell adhesion molecule isoforms in normal and glaucomatous human optic nerve heads. Molecular Brain Res.,1999;74:69-82. – REJDAK R., TOCZOLOWSKI J., KRUKOWSKI J., KAMINSKI M., REJDAK K., STEIMASIAK Z., GRIEB P.: Oral citicoline treatment improves visual pathway function in glaucoma. Med. Sci. Monit., 2003;9:124-128. – RICHLER M., WERNER E.B., THOMAS D.: Risk factors for progression of visual field defects in medically treated patients with glaucoma. Can. J. Ophthalmol., 1982;17:245-248. – ROHEN J.W., WITMER R.: Electron microscopic studies on the trabecular meshwork in glaucoma simplex. Graefe’s Arch. Clin. Exp. Ophthalmol.,1972; 183:251-266. – ROWE M.K., CHUANG D.M.: Lithium neuroprotection: molecular mechanisms and clinical implications. Expert Rev. Mol. Med., 2004;6:1-18. – SCHUETTAUF F., REJDAK R., THALER S., BOLTZ S., LEHACI C., MANKOWSKA A., ZARNOWSKI T., JUNEMANN A., ZAGORSKI Z., ZRENNER E., GRIEB P.: Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in the rat. Exp. Eye Res., 2006;83:1128-1134. – SCHWARTZ M.: Neuroprotection as a treatment for glaucoma: pharmacological and immunological approaches. Eur. J. Ophthalmol., 2001;11(Suppl. 2):S7-S11. – SECADES J.J.: CDP-choline: up-date and review of its pharmacology and clinical use. Methods Find Exp. Clin. Pharmacol., 2001;23(Suppl. B): 1-53. – SHIRAKASHI M., IWATA K., SAWAGUCHI S., ET AL.: Intraocular pressure dependent progression of visual field loss in advanced primary open angle glaucoma: a 15 years follow up. Ophthalmologica, 1993;207:1-5. – SOMMER A., TIELSCH J.M., KATZ J., ET AL.: Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch. Ophthalmol., 1991;109:1090-1095. – SUZUKI Y., SHIRATO S., ADACHI M., HAMADA C.: Risk factors for the progression of treated primary open angle glaucoma: a multivariate life-table analysis. Graefe’s Arch. Clin. Exp. Ophthalmol., 1999;237:463-367. – TEUS M.A., CASTEJON M.A., CALVO M.A., ET AL.: Intraocular pressure as a risk factor for visual field loss in pseudoexfoliative and in primary open-angle glaucoma. Ophthalmology, 1998;105:2225-2229. – VARMA R., QUIGLEY H.A., PEASE M.E.: Changes in optic disk characteristics and the numbers of nerve fibers in experimental glaucoma. Am. J. Ophthalmol., 1992; 114: 554-559. – VIRNO M., PECORI-GIRALDI J., PELLEGRINO N, TAVERNITI L, DE GREGORIO F, SEDRAN L.: Farmaci attivi sull’emodinamica oculare. Boll. Ocul., 1993; 72 (Suppl. 2): S1-S20. – VIRNO M., PECORI-GIRALDI J., LIGUORI A., DE GREGORIO F.: The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol. Scand., 2000; 78 (Suppl., 232): S56-S57. – VOGEL R., CRICK R.P., NEWSON R.B., ET AL.: Association between intraocular pressure and loss of visual field in chronic simple glaucoma. Br. J. Ophthalmol.,1990;74:3-6. – WILSON R., WALKER A.M., DUEKER D.K., CRICK R.P.: Risk factors for rate of progression of glaucomatous visual field loss: a computer-based analysis. Arch. Ophthalmol., 1982;100:737-741.
24
EuVision Peer-reviewed Journal of Ophthalmology 1/10